Rezolute Completed Enrollment for Tumor Hyperinsulinism Trial
The company has finished enrolling participants for its pivotal study of ersodetug to manage severe, insulin-driven hypoglycemia.
Updated on Oct. 14, 2026 in Diabetes
Rezolute has successfully completed enrollment for the Phase 3 upLIFT study, which evaluates the monoclonal antibody ersodetug in 16 patients with tumor hyperinsulinism. This trial aims to address the life-threatening hypoglycemia associated with over-active insulin receptors.
Why it matters
Tumor hyperinsulinism results in dangerous drops in blood sugar that are difficult to manage, and this study explores a new intervention to reduce the need for constant glucose infusions. If successful, this therapy could offer a novel approach for patients who struggle with persistent, insulin-driven hypoglycemia.
The Phase 3 upLIFT study evaluates 16 participants with tumor hyperinsulinism, measuring success by a 50 percent reduction in glucose infusion requirements. While seven of the first eight patients in early testing met the responder threshold, the full trial results are not yet available.
The players
Rezolute
A Redwood City-based biopharmaceutical company focused on developing therapies for metabolic and rare endocrine disorders, including those involving insulin regulation.
The details
Ersodetug works as a monoclonal antibody that targets and inhibits the insulin receptor. By blocking these receptors, the drug aims to prevent the over-activation that leads to severe hypoglycemia in patients with tumor hyperinsulinism. Participants in the study receive 9 mg/kg of the treatment weekly for an 8-week duration to monitor its ability to lower dependence on intravenous glucose.
Timeline
October 14, 2026: The company announced the completion of study enrollment.
Mid-December 2026: Researchers expect to release the topline study data.
2027: Rezolute plans to potentially advance two clinical indications.
Health Landscape
This development represents a critical step in the ongoing evaluation of monoclonal antibodies for rare endocrine conditions within the upLIFT Phase 3 study. It marks a shift from standard supportive care toward mechanism-specific treatments that address insulin receptor over-activity.
Patients dealing with rare conditions characterized by recurrent hypoglycemia should discuss new clinical trial developments with their endocrinologist. If you have been diagnosed with tumor hyperinsulinism, it is worth monitoring future announcements for potential eligibility in expanded access programs.
The takeaway
This trial highlights a potential shift in managing life-threatening hypoglycemia by targeting the insulin receptor directly rather than solely relying on glucose supplementation. Patients with persistent insulin-driven blood sugar issues should consult their physician regarding ongoing clinical research.
What happens next
Topline study results are expected to be released by mid-December 2026.
Further reading
Learn more about the latest research and management approaches in our Diabetes section.
